PET tracer shows promise in prostate cancer patients

CHICAGO – Gallium-68 (Ga-68) RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented November 26 at RSNA 2023. Moreover, the approach could help detect disease that other effective prostate cancer PET radiotracers may miss, said Heying Duan, MD, a nuclear medicine research scientist at Stanford University, during a November 26 scientific session. “You've hear a lot about PSMA. I wanted to introduce a new player in the game: gallium-68 GRPR antagonist,” Duan told attendees, during a scientific session on prostate cancer imaging. Several prostate-specific membrane antigen (PSMA) PET radiotracers for detecting BCR prostate cancer have been approved in the U.S., such as Ga-68 PSMA-11 and F-18 DCFPyl (Pylarify, Lantheus Medical Imaging) and are included in  National Comprehensive Cancer Network guidelines, Duan explained. Yet up to 10% of cases do not express PSMA, she noted. Thus, Duan and colleagues developed a tracer called Ga-68 RM2, which targets other receptors overexpressed in prostate cancer – namely, gastrin-releasing peptide receptors (GRPRs). Previous studies by the team found the tracer is effective at revealing this activity on PET. In her presentation, Duan presented a final analysis of a recently completed phase II/III imaging trial of Ga-68 RM2-PET/MRI compared with MRI alone in patients with biochemically recurrent (BCR) prostate cancer. Out of 209 patients screened between December 12,...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Subspecialties Resources Genitourinary Radiology Nuclear Radiology Conference RSNA 2023 Source Type: news